11:30 AM EST, 02/04/2026 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We cut our target price to USD52 from USD61, implying 16.0x our 2026 EPADS estimate. This is at a discount to its historical forward P/E average of 25x-30x. We think this is justified to reflect the increasing concern about its long-term competitive edge, but above the peer average of 15x to reflect NOVO's higher margin. Novo Nordisk ( NVO ) provided a disappointing 2026 outlook, guiding for adjusted sales and operating profit to decline 5%-13% CER, with management citing lower realized prices from the Most Favored Nations agreement, semaglutide patent expiries in certain international markets, and intensifying competition. While the launch of Wegovy pill has been encouraging, ongoing pricing pressure and rising competitive intensity suggest the operating environment remains challenging, in our view. We cut our 2026 EPADS estimate to DKK20.60 from DKK23.04 to account for the weak outlook and introduce our 2027 estimate at DKK22.30.